Table 2 Characteristics of identified studies (n = 13)
Author | Country | Study period | Study type | Respondent | Method of valuation | Valuation Tariff | Mean Age | Sample size |
|---|---|---|---|---|---|---|---|---|
EQ-5D-3L | ||||||||
 Conner-Spady, et al. (2005) [37] | Canada | 04/1995–10/1998 | Questionnaire | Patients' own health | EQ-5D-3L | UK | 44.7 | 52 |
 Lidgren, et al. (2007) [38] | Sweden | 04–05/2005 | Questionnaire | Patients' own health | EQ-5D-3L | UK | 57 | 345 |
 Kimman, et al. (2009) [39] | Netherland | 07/2005–09/2007 | Questionnaire | Patients' own health | EQ-5D-3L | UK | 55.8 | 192 |
 Freedman, et al. (2010) [40]* | USA | 2010 | Questionnaire | Patients' own health | EQ-5D-3L | US | 45–64 | 1050 |
 Williams, et al. (2011) [41] | UK | 1997 | Questionnaire | Patients' own health | EQ-5D-3L | UK | 72.8 | 255 |
 Yousefi, et al. (2016) [42] | Iran | 11/2013–06/2014 | Questionnaire | Patients' own health | EQ-5D-3L | UK | 46.7 | 163 |
 Wang, et al. (2018) [43] | China | 12/2016–03/2017 | Questionnaire | Patients' own health | EQ-5D-3L | China | 49.1 | 2828 |
 Yu, et al. (2018) [44] | Korea | 01/2012–06/2012 | Questionnaire | Patients' own health | EQ-5D-3L | Korea | 48.9 | 226 |
 Sattar, et al. (2019) [45] | Canada | 10/2014–10/2015 | Questionnaire | Patients' own health | EQ-5D-3L | Canada | 75.3 | 58 |
 Tanaka, et al. (2019) [46]** | Japan | Not stated | Questionnaire | Patients' own health | EQ-5D-3L | UK | 53.4/57.6 | 38 |
 Zigman, et al. (2020) [48] | Croatia | 01/2016–12/2016 | Questionnaire | Patients' own health | EQ-5D-3L | UK | 44.7 | 114 |
EQ-5D-5L | ||||||||
 Yang, et al. (2020) [47] | China | 08/2017–05/20 | Questionnaire | Patients' own health | EQ-5D-5L | China | 51.37 | 446 |
 Etikasari, et al. (2021) [49] | Indonesia | 01/2019–08/2019 | Questionnaire | Patients' own health | EQ-5D-5L | Indonesian | 59.2 | 126 |